HK1065703A1 - Prophylactic and therapeutic use of hydroxysteroids - Google Patents

Prophylactic and therapeutic use of hydroxysteroids

Info

Publication number
HK1065703A1
HK1065703A1 HK04108498.6A HK04108498A HK1065703A1 HK 1065703 A1 HK1065703 A1 HK 1065703A1 HK 04108498 A HK04108498 A HK 04108498A HK 1065703 A1 HK1065703 A1 HK 1065703A1
Authority
HK
Hong Kong
Prior art keywords
hydroxysteroids
prophylactic
therapeutic use
hydroxy
steroids
Prior art date
Application number
HK04108498.6A
Other languages
English (en)
Inventor
Ernst Wuelfert
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of HK1065703A1 publication Critical patent/HK1065703A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK04108498.6A 2001-08-14 2004-10-29 Prophylactic and therapeutic use of hydroxysteroids HK1065703A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0119810A GB2378898A (en) 2001-08-14 2001-08-14 Prophylactic and therapeutic use of hydroxysteroids
PCT/GB2002/003770 WO2003015791A1 (en) 2001-08-14 2002-08-13 Phophylactic and therapeutic use of hydroxysteroids

Publications (1)

Publication Number Publication Date
HK1065703A1 true HK1065703A1 (en) 2005-03-04

Family

ID=9920376

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04108498.6A HK1065703A1 (en) 2001-08-14 2004-10-29 Prophylactic and therapeutic use of hydroxysteroids

Country Status (20)

Country Link
US (1) US8148355B2 (ru)
EP (1) EP1416937B1 (ru)
JP (1) JP4541698B2 (ru)
KR (1) KR100895281B1 (ru)
CN (1) CN1700920B (ru)
AT (1) ATE429919T1 (ru)
AU (1) AU2002321472B2 (ru)
CA (1) CA2457050C (ru)
CY (1) CY1109233T1 (ru)
DE (1) DE60232154D1 (ru)
DK (1) DK1416937T3 (ru)
ES (1) ES2324859T3 (ru)
GB (1) GB2378898A (ru)
HK (1) HK1065703A1 (ru)
IL (2) IL160362A0 (ru)
NO (1) NO334819B1 (ru)
NZ (1) NZ531100A (ru)
PT (1) PT1416937E (ru)
RU (1) RU2329049C2 (ru)
WO (1) WO2003015791A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
KR20090086272A (ko) 2006-11-30 2009-08-11 헌터-플레밍 리미티드 프로스타글란딘/시클로옥시게나제 대사 경로의 조절
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
CN105078954A (zh) * 2015-08-20 2015-11-25 南京华宽信息咨询中心 一种治疗急性肾衰药物及其应用
CN105168197A (zh) * 2015-08-22 2015-12-23 南京华宽信息咨询中心 一种治疗肾功能不全药物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686438A (en) * 1993-03-09 1997-11-11 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
US5846963A (en) * 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
CA2153895A1 (en) * 1993-03-09 1994-09-15 Raymond A. Daynes Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5753640A (en) * 1995-06-07 1998-05-19 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
IT1282289B1 (it) 1995-06-23 1998-03-16 Sigma Tau Ind Farmaceuti 17-idrossiimminoalchil e 17-idrossiimminometilalchenil ciclopentaperidrofenantreni attivi sul sistema cardiovascolare,
AU8968798A (en) 1997-08-29 1999-03-22 Dalhousie University Use of polycyclic steroid compounds for the manufacture of medicament for the treatment of cystic kidney diseases, vascular infarction, uremia and related conditions
AU3467699A (en) * 1998-04-14 1999-11-01 Pharmadigm, Inc. Method for reducing central nervous system impairment
GB0003524D0 (en) * 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone

Also Published As

Publication number Publication date
WO2003015791A1 (en) 2003-02-27
CN1700920A (zh) 2005-11-23
IL160362A (en) 2011-10-31
IL160362A0 (en) 2004-07-25
RU2329049C2 (ru) 2008-07-20
US8148355B2 (en) 2012-04-03
PT1416937E (pt) 2009-07-24
US20040248868A1 (en) 2004-12-09
ATE429919T1 (de) 2009-05-15
RU2004104362A (ru) 2005-05-10
NO334819B1 (no) 2014-06-10
EP1416937A1 (en) 2004-05-12
NZ531100A (en) 2006-02-24
CA2457050A1 (en) 2003-02-27
JP2005506321A (ja) 2005-03-03
DE60232154D1 (de) 2009-06-10
JP4541698B2 (ja) 2010-09-08
CA2457050C (en) 2010-10-12
DK1416937T3 (da) 2009-08-24
AU2002321472B2 (en) 2007-11-08
ES2324859T3 (es) 2009-08-18
GB0119810D0 (en) 2001-10-10
KR20040041577A (ko) 2004-05-17
CY1109233T1 (el) 2014-07-02
KR100895281B1 (ko) 2009-04-29
NO20041057L (no) 2004-03-12
CN1700920B (zh) 2012-05-30
EP1416937B1 (en) 2009-04-29
GB2378898A (en) 2003-02-26

Similar Documents

Publication Publication Date Title
EP1575528A4 (en) TREATMENT PROTECTIVE CYTOKINS FOR THE PROTECTION, RECOVERY AND STRENGTHENING OF RESPECTIVE CELLS, TISSUE AND ORGANS
HK1066482A1 (en) Use os fucans in the treatment of adhesions, arthritis and psoriasis
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
CY1109233T1 (el) Προφυλακτικη και θεραπευτικη χρηση υδροξυστεροειδων
WO2004054432A3 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
NO20013414L (no) Ny anvendelse av melagatran
EP1406648A4 (en) USE OF ANGIOTENSIN I DERIVATIVE AGENT FOR THE TREATMENT AND PREVENTION OF INFECTIOUS HEART DAMAGE AND DISEASES
HK1078460A1 (en) Use of l-carnitine, actyl l-carnitine and propionyl l-carnitine in the manufacture of a combined medicament for the treatment of oligoasthenoteratospermia
WO2004010934A3 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
WO2003045428A3 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer